SECOND LOOK ™
Not publicly available (a 2005 article mentioned a base list price of $139,950 for an older version, second look 700, which is likely outdated).
Regulatory Status Disclosed
Overview
SECOND LOOK™ (also known as SecondLook®) by iCAD, Inc. is a computer-aided detection (CAD) software solution designed to assist radiologists in identifying suspicious lesions during breast cancer screenings. Developed for 2D mammography and computed radiography mammography (CRm) systems, the technology serves as an automated second reader to support clinical decision-making.
The tool is built for radiologists and breast imaging specialists operating in mammography clinics, hospitals, and dedicated women’s imaging centers. It integrates directly into existing digital mammography systems, computed radiography readers, and Picture Archiving and Communication Systems (PACS) to maintain an efficient reading workflow.
Notable Capabilities:
- Lesion Detection: Automatically analyzes 2D mammography images to detect and mark suspicious soft tissue masses and microcalcifications.
- Visual Alerts: Places CAD markers on regions of interest (ROIs) to prompt interpreting physicians to perform a targeted secondary review.
- Workflow Integration: Designed to process images in the background and deliver standardized CAD metrics directly to the radiologist’s reading workstation.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Superior CAD Algorithms
- Patented Artificial Intelligence and Pattern Recognition Technology
- Automatic Identification and Marking of Suspicious Regions
- Detection of Microcalcifications and Masses
- Detection of Architectural Distortions and Focal Asymmetric Densities
- Seamless Integration with Existing Systems
- Workflow Enhancements for Improved Efficiency
- Fast and Precise Reading with Clear Marks
- Added Clinical Confidence and Quality Assurance
- Supports 2D Mammography Images
Use Cases
- Early breast cancer detection
- Assisting radiologists in mammography screening
- Improving workflow efficiency in imaging centers
- Providing quality assurance in breast health programs
- Enhancing clinical confidence in diagnostic interpretation
What Physicians Need to Know
Key Capabilities
Transforms unstructured medical records into structured clinical summaries, interactive timelines (MedChron), and standard-of-care assessments. Extracts CPT4, ICD-10, and HCPCS II codes. Includes an AI Copilot for querying records and providing clinical-grade answers with peer-reviewed references. Supports note-taking, highlighting, and word search within source documents. Enables cohort definition and tracking for quality surveillance. Offers customized and consistent reporting.
Clinical Utility
Significantly reduces medical record review time by 70-90%. Enhances clinical quality assessment for hospitals and health systems, including peer review and incident analysis. Aids workers' compensation entities in identifying at-risk individuals and managing claims. Provides accurate clinical insights for medical-legal professionals, supporting reports and testimony. Compresses complex record comprehension from days to minutes.
Integration Options
Available as Software-as-a-Service (SaaS), via API, or as an embedded agent. Designed to integrate with existing healthcare IT infrastructure, including EHR feeds, claims systems, and case management platforms, with configurable data routing and access controls.
Compliance Status
HIPAA Compliant with Business Associate Agreements (BAAs) in place. SOC 2 Type II Certified, demonstrating robust security controls. Utilizes a Closed-System AI, ensuring client data remains within SecondLook's secure environment without being used for model training or cross-tenant leakage. Includes safety guardrails, defined escalation protocols, ongoing bias testing, clinical quality assurance, and traceable audit logs.
Pricing Model
Offered as 'Clinical Intelligence as a Service' for enterprise clients, suggesting a structured engagement model rather than a simple software license. Provides a 'free first case' (up to 2000 pages) and lifetime discounts for ICHCC credentialed practitioners.
User Experience
Designed for quick setup ('sign up in minutes, no IT setup, no lengthy onboarding'). Allows easy upload of medical records in various formats. Features interactive timelines and polished report exports. The AI is physician-built to interpret records similarly to an experienced clinician, aiming to reduce administrative burden.
Support Quality
SecondLook Health's clinical and product teams are actively involved in calibrating, validating, and continuously tuning the system to align with client-specific operations, case mixes, and evolving regulations. Offers initial 30-minute working sessions for Proof of Concept (POC) scoping.
Implementation Complexity
For enterprise clients, implementation follows a structured engagement (Scope, Calibrate, Validate, Integrate, Deploy) with continuous tuning. This involves mapping workflows, configuring to standards, clinical expert validation, and integration with existing systems. Aims for minimal IT setup for individual users.
Evidence Base
The AI is physician-built and validated by practicing clinicians. Claims 99% accuracy (3rd party validated). Used and validated by hospital systems and insurance companies. The AI Copilot can retrieve peer-reviewed literature, and all insights are linked to source documentation with citations.
Physician Tip
Leverage SECOND LOOKu2122 to dramatically reduce time spent on medical record review, freeing up valuable time for direct patient care and complex decision-making. Utilize the AI Copilot for quick, evidence-based answers to clinical questions. Always verify AI-generated insights against source documents, as the tool provides complete traceability. Integrate the platform into existing workflows to streamline administrative tasks and enhance quality assurance processes, particularly for peer reviews and standard of care assessments. For medical-legal cases, the detailed chronologies and traceable findings can significantly strengthen your expert analysis.
SECOND LOOKu2122 offers versatile integration options (SaaS, API, embedded agent) to ensure compatibility with diverse healthcare IT environments. Seamlessly connecting with EHRs, claims systems, and case management platforms is crucial for maximizing its utility and avoiding fragmented workflows. Prioritize integration planning to ensure data flows efficiently and securely, aligning with existing access controls and data routing protocols.
Details
| Category | Oncology AI |
| Pricing | Not publicly available (a 2005 article mentioned a base list price of $139,950 for an older version, second look 700, which is likely outdated). — Contact vendor for current pricing. |
| Deployment | On-premise (integrated with mammography systems and hospital/clinic IT infrastructure) |
| Compliance | |
| BAA Available | Yes AI-estimated |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status |
Yes AI-estimated The original Premarket Approval (PMA) P010034 for the Second Look™ Computer-Aided Detection System was granted on January 31, 2002, for identifying and marking regions of interest on mammograms to assist radiologists in breast cancer screening. |
| Integrations | |
| EHR | Not specified |
| Specialties | General Surgery, Oncology, Radiology |
What the Web Says
SECOND LOOKu2122 by iCAD is a computer-aided detection (CAD) system designed to assist radiologists in identifying potential abnormalities in mammograms. Reviews from physicians and tech reviewers generally highlight its role in improving detection rates and reducing false negatives, though some point to the need for careful integration into workflow and potential for false positives.
Overall: PositiveStrengths
- Aids in early detection of breast cancer
- Reduces the likelihood of missed lesions
- Can improve radiologist confidence
- Integrates with existing mammography systems
- FDA approved technology
- Potentially reduces recall rates for some types of lesions
Limitations
- Can generate false positives, leading to unnecessary follow-ups
- Requires careful interpretation by radiologists, not a standalone diagnostic tool
- Initial setup and integration can be complex
- Cost of implementation may be a barrier for some facilities
- May increase reading time for some cases due to additional markers
- Specific performance can vary based on image quality and radiologist experience
Based on reviews from: iCADmed.com, Radiology Today, Journal of Digital Imaging, AuntMinnie.com, PubMed, Healthcare IT News
Last updated: 2026-07-20
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate SECOND LOOK ™
Press & Coverage
iCAD
Physician Ai Tools
SECOND LOOKu2122 by iCAD, Inc. is an FDA-cleared, AI-powered solution for breast cancer detection, also licensed by Health Canada. The company provides news, demos, and interviews about its medical technology.
2026-04
PMC
Computer-Aided Detection of Breast Cancer u2013 Have All Bases Been Covered?
This article discusses the evolution of computer-aided detection (CAD) systems for mammography, noting that the iCAD Second Look CAD system received FDA approval in 2002. It also highlights debates surrounding the efficacy of CAD systems in improving diagnostic accuracy.
2008-02
PMC - NIH
Deep Learning-Based Artificial Intelligence for Mammography
This peer-reviewed article from August 2021 compares conventional CAD, including iCAD's SecondLook v7.2, with newer AI-CAD algorithms for mammography. It notes that conventional CAD often shows multiple areas for radiologist attention, while AI-CAD aims to enhance efficiency and accuracy.
2021-08
HealthpointCapital
HealthpointCapital u2014 Healthcare Investor Profile | physicianaitools ...
HealthpointCapital's profile mentions iCAD as a medical technology company with an FDA-cleared AI solution, SECOND LOOKu2122. The company focuses on cancer detection and therapy solutions.
2026-05
PitchBook
iCAD 2026 Company Profile: Valuation, Investors, Acquisition | PitchBook
iCAD Inc. is described as a medical technology company providing cancer detection and therapy solutions, operating in a segment that includes AI and Computer-Aided Detection (CAD) systems for mammography, MRI, and CT. PitchBook indicates iCAD was acquired on July 17, 2025.
2025-07
The Imaging Wire
Arterys Archives - The Imaging Wire
An October 2022 article reports on Arterys' global distribution agreement with iCAD, making iCAD's breast health solutions, including 2D and 3D mammography detection and personalized risk screening, available as a cloud-based SaaS solution for the first time.
2022-10
RSNA Journals
Checklist for Artificial Intelligence in Medical Imaging (CLAIM): A Guide for Authors and Reviewers | Radiology - RSNA Journals
This peer-reviewed guide from March 2020 for authors and reviewers of AI manuscripts in medical imaging mentions iCAD in the context of author disclosures, indicating a consultant relationship with iCAD.
2020-03
MedTech World
Is it Time for An AI Regulatory Framework? - MedTech World
A July 2026 article discusses the need for AI regulatory frameworks in medical devices, emphasizing patient safety and cybersecurity. While not directly about SECOND LOOKu2122, it provides context for regulatory discussions relevant to AI in healthcare.
2026-07
Videos
Product demos, reviews, and walkthroughs for SECOND LOOK ™.
ud83dudd25Cutting the ASICS Magic Speed 3 in half! ud83dudd2a Shocking Results! ud83eudd2f #shorts #fyp
Frequently Asked Questions
SECOND LOOKu2122 offers various AI tools for oncology. For instance, 'Second Look Cancer' assists in clinical trial matching for colorectal cancer by filtering eligible trials based on patient-specific data, while 'SecondLooku00ae' (by iCAD) integrates with 2D mammography systems to highlight suspicious regions for radiologists. 'SecondLook Health' can streamline medical record review, providing clinical summaries and interactive timelines for complex cases, which can be valuable for quality assurance or legal contexts within oncology.
SECOND LOOKu2122 AI tools, particularly 'SecondLook Health', are designed to be HIPAA compliant and often feature SOC2 Type II protection for data security. For diagnostic tools like 'SecondLooku00ae' in mammography, FDA clearance is typically required, indicating adherence to medical device regulations. Patient data used for clinical trial matching by 'Second Look Cancer' is encrypted and never sold, with the patient controlling contact with trial sites.
For mammography, 'SecondLooku00ae' utilizes patented algorithms to identify suspicious regions, aiming to improve early cancer detection and workflow efficiency by complementing the radiologist's review. However, AI tools in oncology, in general, can have limitations such as inconsistent performance after deployment due to biases in algorithm development, and may sometimes rely on statistical 'shortcuts' rather than true biological signals. It's crucial to remember that these tools are assistive and do not replace molecular testing or physician judgment.
Alternatives vary depending on the specific SECOND LOOKu2122 tool. For AI-powered mammography CAD, other vendors offer similar computer-aided detection systems like ProFound AIu00ae. For clinical trial matching, manual review by staff or other digital matching platforms exist. For medical record analysis, traditional manual chart review is the primary alternative, though other AI-powered clinical decision support systems like IBM Watson for Oncology offer broader capabilities in treatment planning and evidence synthesis.
Pricing for SECOND LOOKu2122 tools varies by product and user. 'Second Look Cancer' for patients is completely free. For professional tools like 'SecondLook Health' for medical record analysis, pricing is often tiered based on volume, with potential discounts for professional organizations, and aims to offer a significant reduction in review time and cost. While specific pricing for 'SecondLooku00ae' (mammography CAD) isn't publicly detailed, such systems are typically licensed to healthcare facilities, offering ROI through improved efficiency and potentially earlier detection.
SECOND LOOKu2122 AI tools are designed to augment, not replace, physician judgment in oncology. For example, 'SecondLooku00ae' for mammography provides a 'second look' to assist radiologists in identifying areas of concern, which they then factor into their interpretation. Similarly, 'SecondLook Health' provides organized clinical data and insights to help physicians make more informed decisions, emphasizing that the AI understands clinical context and standard of care, but the final decision rests with the clinician.
Beyond breast cancer screening and colorectal cancer trial matching, 'SecondLook Health' offers broader applications in oncology by analyzing complex medical records for hospitals and health systems. This includes peer review, incident report analysis, and cohort-level quality surveillance, which can assess clinical narratives and standard of care more efficiently than manual methods. This allows for deeper insights into quality data and can support various clinical and administrative functions within an oncology department.
Suggest an Edit →
| Last Verified: 2026-04-20 | First Added: 2026-04-20
Investors who backed SECOND LOOK ™
Funded through the company that built this tool.
